摘要
蛋白质是药物给药系统发展中用来合成聚合物的天然配体,它们中的一些已经被美国食品药品监督管理局(FDA)认为与药物传输目的的安全性有关。血清蛋白是人体血液中最丰富的蛋白质。对白蛋白为基础的给药载体药物应用的探索的兴趣,尤其是对于化疗药物给药系统,在最近几年有所增加。白蛋白在合成聚合物上具有许多的优点,例如它具有生物相容性、生物降解性、细胞毒性低以及与其他多种药物具有很好的结合能力。微型和纳米载体不仅防止药物活性成分退化,而且提供了一个可控的缓释药物的方式。因为现有的肿瘤化疗药物既不能定位肿瘤细胞,也不能针对特定的肿瘤细胞,药物从载体里面缓慢释放将对把癌细胞内作为目标有帮助。本文旨在提供一个关于白蛋白在肿瘤化疗中作为一个给药载体的药物应用的综述。
关键词: 白蛋白,癌症,化疗,给药,微球体,纳米颗粒
图形摘要
Current Cancer Drug Targets
Title:Bioactive Albumin-Based Carriers for Tumour Chemotherapy
Volume: 14 Issue: 8
Author(s): Yasser Shahzad, Ikram Ullah Khan, Talib Hussain, Alamgeer, Christophe A. Serra, Syed A.A. Rizvi, Minja Gerber and Jeanetta du Plessis
Affiliation:
关键词: 白蛋白,癌症,化疗,给药,微球体,纳米颗粒
摘要: Proteins are posed as the natural counterpart of the synthetic polymers for the development of drug delivery systems and few of them, have been regarded safe for drug delivery purposes by the United States Food and Drug Administration (FDA). Serum albumin is the most abundant protein in human blood. Interest in the exploration of pharmaceutical applications of albumin-based drug delivery carriers, especially for the delivery of chemotherapeutic agents, has increased in recent years. Albumin has several advantages over synthetic polymers, as it is biocompatible, biodegradable, has low cytotoxicity and has an excellent binding capacity with various drugs. Micro- and nano-carriers not only protect active pharmaceutical ingredients against degradation, but also offer a prolonged release of drugs in a controlled fashion. Since existing tumour chemotherapeutic agents neither target tumour cells, nor are they specific to tumour cells, a slow release of drugs from carriers would be beneficial in targeting carcinogenic cells intracellularly. This article aims at providing an overview of pharmaceutical applications of albumin as a drug delivery carrier in tumour chemotherapy.
Export Options
About this article
Cite this article as:
Yasser Shahzad, Ikram Ullah Khan, Talib Hussain, Alamgeer, Christophe A. Serra, Syed A.A. Rizvi, Minja Gerber and Plessis du Jeanetta, Bioactive Albumin-Based Carriers for Tumour Chemotherapy, Current Cancer Drug Targets 2014; 14 (8) . https://dx.doi.org/10.2174/1568009614666141028100640
DOI https://dx.doi.org/10.2174/1568009614666141028100640 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives
Current Medicinal Chemistry The Physiological Basis and Nutritional Function of Alpha-ketoglutarate
Current Protein & Peptide Science Potential Therapeutic Application of Chondroitin Sulfate/Dermatan Sulfate
Current Drug Discovery Technologies Immunotherapy Approaches in Cancer Treatment
Current Pharmaceutical Biotechnology Structure-Editing of Nucleic Acids for Selective Targeting of RNA
Current Topics in Medicinal Chemistry CORAL: Classification Model for Predictions of Anti-Sarcoma Activity
Current Topics in Medicinal Chemistry The Effect of Krill Oil and n-3 Polyunsaturated Fatty Acids on Human Osteosarcoma Cell Proliferation and Migration
Current Drug Targets The mAP-KL Algorithm Combined with Mutual Information Network Used to Screen Hub Genes in Osteosarcoma
Current Bioinformatics Insights into Targeting NEMO for Pharmacological Regulation
Current Drug Targets Synthetic Aziridines in Medicinal Chemistry: A Mini-Review
Mini-Reviews in Medicinal Chemistry Transforming Growth Factor-β: A Molecular Target for the Future Therapy of Glioblastoma
Current Pharmaceutical Design Anal Cancer: Focus on HIV-Positive Patients in the HAART Era
Current HIV Research A Systematic Review of Genes Involved in the Inverse Resistance Relationship Between Cisplatin and Paclitaxel Chemotherapy: Role of BRCA1
Current Cancer Drug Targets Metallothioneins and Cancer
Current Protein & Peptide Science Tumor Stroma Manipulation By MSC
Current Drug Targets The Biology and Medicinal Chemistry of Epothilones
Current Medicinal Chemistry - Anti-Cancer Agents Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers
Recent Patents on Anti-Cancer Drug Discovery A Review of Pediatric Mediastinal Masses and Castlemans Disease
Current Pediatric Reviews MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Cardiac Disease
Recent Patents on Biomarkers Effect of HAART on Salivary Composition and Oxidative Profile in HIVInfected Patients
Current HIV Research